Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia E Maxson

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|May 31, 2020
Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemiaTheodore P Braun, Cody Coblentz, Brittany M Curtiss, et al.
Current Oncology (Toronto, Ont.)|February 24, 2022
Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute LeukemiaFranziska C Adam, Jakub Szybinski, Jörg P Halter, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 5, 2013
Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscleTheodore P Braun, Aaron J Grossberg, Stephanie M Krasnow, et al.
Blood|October 2, 2013
The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibitionAngela G Fleischman, Julia E Maxson, Samuel B Luty, et al.
Blood|April 28, 2022
Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasmsSarah A Carratt, Garth L Kong, Brittany M Curtiss, et al.
Leukemia|March 9, 2023
RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia developmentSarah A Carratt, Garth L Kong, Cody Coblentz, et al.
Science Signaling|July 19, 2018
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemiaChelsea Jenkins, Samuel B Luty, Julia E Maxson, et al.
BMC Bioinformatics|October 9, 2025
Correction: CITEViz: interactively classify cell populations in CITE-Seq via a flow cytometry-like gating workflow using R-ShinyGarth L Kong, Thai T Nguyen, Wesley K Rosales, et al.
BMC Bioinformatics|April 2, 2024
CITEViz: interactively classify cell populations in CITE-Seq via a flow cytometry-like gating workflow using R-ShinyGarth L Kong, Thai T Nguyen, Wesley K Rosales, et al.
Cancer Research|June 3, 2015
Therapeutically Targetable ALK Mutations in LeukemiaJulia E Maxson, Monika A Davare, Samuel B Luty, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|May 31, 2020
Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemiaTheodore P Braun, Cody Coblentz, Brittany M Curtiss, et al.
Current Oncology (Toronto, Ont.)|February 24, 2022
Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute LeukemiaFranziska C Adam, Jakub Szybinski, Jörg P Halter, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 5, 2013
Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscleTheodore P Braun, Aaron J Grossberg, Stephanie M Krasnow, et al.
Blood|October 2, 2013
The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibitionAngela G Fleischman, Julia E Maxson, Samuel B Luty, et al.
Blood|April 28, 2022
Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasmsSarah A Carratt, Garth L Kong, Brittany M Curtiss, et al.
Leukemia|March 9, 2023
RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia developmentSarah A Carratt, Garth L Kong, Cody Coblentz, et al.
Science Signaling|July 19, 2018
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemiaChelsea Jenkins, Samuel B Luty, Julia E Maxson, et al.
BMC Bioinformatics|October 9, 2025
Correction: CITEViz: interactively classify cell populations in CITE-Seq via a flow cytometry-like gating workflow using R-ShinyGarth L Kong, Thai T Nguyen, Wesley K Rosales, et al.
BMC Bioinformatics|April 2, 2024
CITEViz: interactively classify cell populations in CITE-Seq via a flow cytometry-like gating workflow using R-ShinyGarth L Kong, Thai T Nguyen, Wesley K Rosales, et al.
Cancer Research|June 3, 2015
Therapeutically Targetable ALK Mutations in LeukemiaJulia E Maxson, Monika A Davare, Samuel B Luty, et al.
Pageof 5